Robert Blum: Thank you.
Operator: Thank you. And our next question will come from Roanna Ruiz from Leerink Partners. Your line is open.
Robert Blum: Good afternoon.
Roanna Ruiz : Good afternoon. Thanks. So a quick one from me. I was curious if you could talk a bit more about the clinical meaningfulness of the 99.5% of monitoring echoes that did not need dose reductions in the FOREST data? And how does it actually compare to what physicians are seeing in clinical practice today with mavacamten?
Robert Blum: We’ll address that but I hope you’ll understand if we don’t make a comparative statement to mavacamten. But Fady, could I ask you to take that?
Fady Malik : Sure. I think the reason we made that point like I know the reason, we made that point in terms of the number of echoes, the number that don’t require a change in management is to give some flavor to what the burden of monitoring it. If you do a test to monitor for something, and it only has a meaningful outcome in less than 0.5% of the measurements that you do. You have to ask yourself are you appropriately deploying resources in a way that is efficient and are there better ways to deploy those resources that can maintain the same degree of safety. But not necessarily burden the system quite as heavily. So, I think incumbent on us to understand what the determinants are of those very infrequent events, how do we anticipate them and to eliminate what our 99% of tests that have no clinical impact, but cost the system a lot in terms of resources time and money. So I think that’s ultimately why we made those points in our presentation.
Roanna Ruiz: Got it. Thanks.
Robert Blum: Thank you.
Operator: Thank you. And our next question will come from Justin Kim from Oppenheimer & Co. Your line is open.
Robert Blum: Hi, Justin.
Justin Kim: Hi, Robert. Good evening, everyone. Sorry, I may have joined a little bit late, but I just had a quick question on the — I guess the SEQUOIA study and inclusion of patients who are refractory to SRT. Just because of I guess the young women experience was presented a few weeks back, curious like if that experience would be similar to what we saw in EXPLORER? And any color there?
Robert Blum: So I think I just want to make sure that we’re using the right language. I don’t know that refractory to SRT is the right way to put it. What we were pointing out was those patients who were eligible for SRT pretreatment versus post treatment. But maybe Fady you could speak to that.
Fady Malik: Yeah. No, that’s right. These patients meet the criteria for SRT which is that they have a New York Heart Association class of three or more and that they have a gradient of 50 or more. So in FOREST we a couple of weeks ago looked again at the percentage of those patients who remained eligible for SRT, once they started aficamten treatment and only about 10% of them met those criteria after therapy where of the ones that had met at the time of therapy. So we’re not necessarily inclusive of patients that are refractory to SRT. They just meet the criteria for SRT.
Justin Kim: Okay. I guess maybe just a clarification. I think there were patients who had residual gradients following surgery. And just wondering if the study includes those patients here just given that these patients do benefit have been shown to benefit?
Robert Blum: Yeah. No. And patients that had septal reduction therapy is an exclusion for this particular trial for SEQUOIA.
Justin Kim: Okay. Great. And maybe as a segue I mean just on the FOREST presentation, is there a sort of natural timing for the HCM cohort and when we might be able to see any added long-term treatment there?
Robert Blum: And with regards to FOREST. Yeah. I mean, I think what we want to see is the NCM cohort to age a little bit, so that we have about at least six months to a year’s worth of follow-up before we report those data. So you’ll probably see them in 2024.
Justin Kim: Okay. We’ll look forward to that ICC or ACC.
Robert Blum: Thank you.
Operator: Thank you. And I am showing no further questions from our phone line. I’d now like to turn the conference back over to Robert Blum, President and CEO for any closing remarks.
Robert Blum: Thank you, operator, and thanks very much to everybody for joining us on this call today. We covered a lot of ground. So I won’t try to synthesize or summarize that other than to say, we do look forward to the results from SEQUOIA-HCM and top lining them later in this quarter in late December. We thank you for your continued support your interest in Cytokinetics. And operator with that we can now conclude the call.
Operator: Thank you. This concludes today’s conference call. Thank you for your participation. You may now disconnect. Everyone have a great day.
